Literature DB >> 10569789

Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

B P Hurley1, M Jacewicz, C M Thorpe, L L Lincicome, A J King, G T Keusch, D W Acheson.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) is an important food-borne pathogen that causes hemolytic-uremic syndrome. Following ingestion, STEC cells colonize the intestine and produce Shiga toxins (Stx), which appear to translocate across the intestinal epithelium and subsequently reach sensitive endothelial cell beds. STEC cells produce one or both of two major toxins, Stx1 and Stx2. Stx2-producing STEC is more often associated with disease for reasons as yet undetermined. In this study, we used polarized intestinal epithelial cells grown on permeable filters as a model to compare Stx1 and Stx2 movement across the intestinal epithelium. We have previously shown that biologically active Stx1 is able to translocate across cell monolayers in an energy-dependent, saturable manner. This study demonstrates that biologically active Stx2 is also capable of movement across the epithelium without affecting barrier function, but significantly less Stx2 crossed monolayers than Stx1. Chilling the monolayers to 4 degrees C reduced the amount of Stx1 and Stx2 movement by 200-fold and 20-fold respectively. Stx1 movement was clearly directional, favoring an apical-to-basolateral translocation, whereas Stx2 movement was not. Colchicine reduced Stx1, but not Stx2, translocation. Monensin reduced the translocation of both toxins, but the effect was more pronounced with Stx1. Brefeldin A had no effect on either toxin. Excess unlabeled Stx1 blocks the movement of (125)I-Stx1. Excess Stx2 failed to have any effect on Stx1 movement. Our data suggests that, despite the many common physical and biochemical properties of the two toxins, they appear to be crossing the epithelial cell barrier by different pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569789      PMCID: PMC97081          DOI: 10.1128/IAI.67.12.6670-6677.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

Authors:  A Donohue-Rolfe; D W Acheson; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

2.  Quantification of protein transcytosis in the human colon carcinoma cell line CaCo-2.

Authors:  M Heyman; A M Crain-Denoyelle; S K Nath; J F Desjeux
Journal:  J Cell Physiol       Date:  1990-05       Impact factor: 6.384

3.  Immunologic therapy for hemolytic-uremic syndrome.

Authors:  D V Milford; C M Taylor; P E Rose; T C Roy; B Rowe
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

4.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

Review 5.  Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli.

Authors:  L K Pickering; T G Obrig; F B Stapleton
Journal:  Pediatr Infect Dis J       Date:  1994-06       Impact factor: 2.129

Review 6.  Perturbation of vesicular traffic with the carboxylic ionophore monensin.

Authors:  A M Tartakoff
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

7.  Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2.

Authors:  S M Scotland; G A Willshaw; H R Smith; B Rowe
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

8.  Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.

Authors:  E A Wadolkowski; L M Sung; J A Burris; J E Samuel; A D O'Brien
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

9.  Edema disease-like brain lesions in gnotobiotic piglets infected with Escherichia coli serotype O157:H7.

Authors:  D H Francis; R A Moxley; C Y Andraos
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

10.  Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections.

Authors:  S M Ostroff; P I Tarr; M A Neill; J H Lewis; N Hargrett-Bean; J M Kobayashi
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

View more
  35 in total

1.  Intestinal Shiga toxin-producing Escherichia coli bacteria mitigate bovine leukemia virus infection in experimentally infected sheep.

Authors:  Witold A Ferens; Rowland Cobbold; Carolyn J Hovde
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Intestinal damage in enterohemorrhagic Escherichia coli infection.

Authors:  Zivile D Békássy; Carla Calderon Toledo; Gustav Leoj; Anncharlotte Kristoffersson; Shana R Leopold; Maria-Thereza Perez; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2010-09-01       Impact factor: 3.714

3.  Enterohemorrhagic Escherichia coli infection stimulates Shiga toxin 1 macropinocytosis and transcytosis across intestinal epithelial cells.

Authors:  Valeriy Lukyanenko; Irina Malyukova; Ann Hubbard; Michael Delannoy; Edgar Boedeker; Chengru Zhu; Liudmila Cebotaru; Olga Kovbasnjuk
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-10       Impact factor: 4.249

4.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Latrunculin B facilitates Shiga toxin 1 transcellular transcytosis across T84 intestinal epithelial cells.

Authors:  Irina Maluykova; Oksana Gutsal; Marina Laiko; Anne Kane; Mark Donowitz; Olga Kovbasnjuk
Journal:  Biochim Biophys Acta       Date:  2008-02-20

6.  An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.

Authors:  Miho Watanabe-Takahashi; Toshio Sato; Taeko Dohi; Noriko Noguchi; Fumi Kano; Masayuki Murata; Takashi Hamabata; Yasuhiro Natori; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

7.  Shiga toxins induce autophagy leading to differential signalling pathways in toxin-sensitive and toxin-resistant human cells.

Authors:  Moo-Seung Lee; Rama P Cherla; Matthew H Jenson; Dinorah Leyva-Illades; Margarita Martinez-Moczygemba; Vernon L Tesh
Journal:  Cell Microbiol       Date:  2011-07-04       Impact factor: 3.715

8.  Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue.

Authors:  Teresa M DesRochers; Erica Palma Kimmerling; Dakshina M Jandhyala; Wassim El-Jouni; Jing Zhou; Cheleste M Thorpe; John M Leong; David L Kaplan
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

Review 9.  Induction of apoptosis by Shiga toxins.

Authors:  Vernon L Tesh
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

10.  Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration.

Authors:  B P Hurley; C M Thorpe; D W Acheson
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.